These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28334757)

  • 1. Perturbations in cell signaling elicit early cardiac defects in mucopolysaccharidosis type II.
    Costa R; Urbani A; Salvalaio M; Bellesso S; Cieri D; Zancan I; Filocamo M; Bonaldo P; Szabò I; Tomanin R; Moro E
    Hum Mol Genet; 2017 May; 26(9):1643-1655. PubMed ID: 28334757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII).
    Bellesso S; Salvalaio M; Lualdi S; Tognon E; Costa R; Braghetta P; Giraudo C; Stramare R; Rigon L; Filocamo M; Tomanin R; Moro E
    Hum Mol Genet; 2018 Jul; 27(13):2262-2275. PubMed ID: 29648648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery.
    Cardone M; Polito VA; Pepe S; Mann L; D'Azzo A; Auricchio A; Ballabio A; Cosma MP
    Hum Mol Genet; 2006 Apr; 15(7):1225-36. PubMed ID: 16505002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel functional role of iduronate-2-sulfatase in zebrafish early development.
    Moro E; Tomanin R; Friso A; Modena N; Tiso N; Scarpa M; Argenton F
    Matrix Biol; 2010 Jan; 29(1):43-50. PubMed ID: 19761845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice.
    Polito VA; Cosma MP
    Am J Hum Genet; 2009 Aug; 85(2):296-301. PubMed ID: 19679226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II.
    Hong SH; Chu H; Kim KR; Ko MH; Kwon SY; Moon IJ; Chung WH; Cho YS; Kim CH; Suh MW; Choi EW; Sohn YB; Park SW; Kim SH; Cho SY; Ko AR; Jin DK
    Am J Med Genet A; 2012 Sep; 158A(9):2131-8. PubMed ID: 22847837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.
    Rybová J; Ledvinová J; Sikora J; Kuchař L; Dobrovolný R
    J Inherit Metab Dis; 2018 Mar; 41(2):221-229. PubMed ID: 29168031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
    Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II.
    Wakabayashi T; Shimada Y; Akiyama K; Higuchi T; Fukuda T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Hum Gene Ther; 2015 Jun; 26(6):357-66. PubMed ID: 25761450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt/β-catenin and sonic hedgehog pathways interact in the regulation of the development of the dorsal mesenchymal protrusion.
    Briggs LE; Burns TA; Lockhart MM; Phelps AL; Van den Hoff MJ; Wessels A
    Dev Dyn; 2016 Feb; 245(2):103-13. PubMed ID: 26297872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
    Sonoda H; Morimoto H; Yoden E; Koshimura Y; Kinoshita M; Golovina G; Takagi H; Yamamoto R; Minami K; Mizoguchi A; Tachibana K; Hirato T; Takahashi K
    Mol Ther; 2018 May; 26(5):1366-1374. PubMed ID: 29606503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
    Cho SY; Lee J; Ko AR; Kwak MJ; Kim S; Sohn YB; Park SW; Jin DK
    Orphanet J Rare Dis; 2015 Oct; 10():141. PubMed ID: 26520066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy of Hunter syndrome: evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS).
    Friso A; Tomanin R; Zanetti A; Mennuni C; Calvaruso F; La Monica N; Marin O; Zacchello F; Scarpa M
    Biochim Biophys Acta; 2008 Oct; 1782(10):574-80. PubMed ID: 18675343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy.
    Polito VA; Abbondante S; Polishchuk RS; Nusco E; Salvia R; Cosma MP
    Hum Mol Genet; 2010 Dec; 19(24):4871-85. PubMed ID: 20876612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convergent molecular mechanisms underlying cognitive impairment in mucopolysaccharidosis type II.
    Corrêa T; Poswar F; Santos-Rebouças CB
    Metab Brain Dis; 2022 Aug; 37(6):2089-2102. PubMed ID: 34797484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts.
    Friso A; Tomanin R; Alba S; Gasparotto N; Puicher EP; Fusco M; Hortelano G; Muenzer J; Marin O; Zacchello F; Scarpa M
    J Gene Med; 2005 Nov; 7(11):1482-91. PubMed ID: 15966019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucopolysaccharidosis type II zebrafish model exhibits early impaired proteasomal-mediated degradation of the axon guidance receptor Dcc.
    Manzoli R; Badenetti L; Bruzzone M; Macario MC; Rubin M; Dal Maschio M; Roveri A; Moro E
    Cell Death Dis; 2024 Apr; 15(4):269. PubMed ID: 38627369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-myeloablative preconditioning with ACK2 (anti-c-kit antibody) is efficient in bone marrow transplantation for murine models of mucopolysaccharidosis type II.
    Yokoi T; Yokoi K; Akiyama K; Higuchi T; Shimada Y; Kobayashi H; Sato T; Ohteki T; Otsu M; Nakauchi H; Ida H; Ohashi T
    Mol Genet Metab; 2016 Nov; 119(3):232-238. PubMed ID: 27590924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of maternal-zygotic ugdh mutants reveals divergent roles for HSPGs in vertebrate embryogenesis and provides new insight into the initiation of left-right asymmetry.
    Superina S; Borovina A; Ciruna B
    Dev Biol; 2014 Mar; 387(2):154-66. PubMed ID: 24462977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.